Onkologie. 2012:6(5):284-286

Gefitinib in treatment of non-small-cell-lung cancer

Ondřej Venclíček1, Marcela Tomíšková1, Jana Skřičková1, Jitka Hausnerová2, Mojmír Moulis2 Blanka Robešová2, Monika Bajerová3, Dana Dvořáková3
1 Klinika nemocí plicních a tuberkulózy, FN Brno, Bohunice a LF MU v Brně
2 Patologicko-anatomický ústav, FN Brno, Bohunice a LF MU v Brně
3 Centrum molekulární biologie a genové terapie při Interní hematoonkologické klinice, FN Brno, Bohunice a LF MU v Brně

Lung carcinoma is the most common cause of death among cancer patients. Non-small-cell-lung cancer is the most frequent histological

type of lung carcinoma. Gefitinib is intended for biological treatment of locally advanced or metastatic non-small-cell-lung cancer

in patients with activation mutation of epidermal factor growth receptor, in first line of treatment, without previous chemothrapy. Case

study discusses two patients treated with gefitinib, with similar initial parameters, but diferent outcomes of the treatment.

Keywords: gefitinib, biological treatment, non-small-cell-lung-cancer, epidermal factor growth receptor

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Venclíček O, Tomíšková M, Skřičková J, Hausnerová J, Robešová MMB, Bajerová M, Dvořáková D. Gefitinib in treatment of non-small-cell-lung cancer. Onkologie. 2012;6(5):284-286.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tomíšková M, Skřičková J, Hausnerová J, Moulis M, Robešová B, Bajerová M, Dvořáková D. Klinické zkušenosti s gefitinibem v léčbě nemocných s nemalobuněčným karcinomem plic. Farmakoterapie 2012: 2.
    2. Skřičková J, Pešek M, Kolek V, a kol. Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Stud. Pneumol. Phtiseol. 2009; 69: 62-68.
    3. Kolektiv autorů Astra Zeneca. Iressa v léčbě nemalobuněčného karcinomu plic (NSCLC), nádory bronchu, plíce a pleury. Nové léky v onkologické praxi 2011: 27-37.
    4. http://ec.europa.eu/research/health/pdf/event06/12052011/anne-debock_en.pdf.
    5. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refraktory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537. Go to original source... Go to PubMed...
    6. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818. Go to original source... Go to PubMed...
    7. Yang CH, Fukuoka M, Mok TS, et al. Final overall survival results from a phase III, randomised, open label, first-line study of gefitinib v. carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS) Ann Oncol 2010; 21(Suppl. 8): viii122-161. Go to original source... Go to PubMed...
    8. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4(6): 366-369. Go to original source... Go to PubMed...
    9. Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crin? L. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer 2004; 90: 82-86. doi: 10.1038/sj.bjc.6601470. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.